Zhu Changzheng, Wang Kuijie, Yu Ting, Liu Huaqing
Department of Internal Neurology, Zhangqiu District People's Hospital Ji'nan 250200, Shandong, China.
Am J Transl Res. 2021 Apr 15;13(4):2717-2723. eCollection 2021.
To analyze the effects of botulinum toxin type A (BtA) in the treatment of patients with Parkinson's disease and depression.
89 patients with Parkinson's disease and depression were assigned into control group and observation group by random number table method, of which 44 patients in the control group were treated with sertraline and 45 patients in the observation group were treated with BtA. The two groups were compared in terms of mood, cognitive function and adverse reactions.
The Hamilton Depression Self-Assessment Scale (HAMD) scores of the two groups following treatment were lower than those before treatment while the Mini-Mental State Examination (MMSE) scores were higher than those before treatment (P<0.05). The incidence rate of adverse events was 11.11% in the observation group and 29.55% in the control group (<0.05). The Pittsburgh sleep quality index (PSQI) scores and 39-item PD Questionnaire (PDQ-39) scores after 2 and 3 months of treatment and 2 months after completion of treatment were lower than those before treatment (<0.05).
Patients with Parkinson's disease and depression receiving BtA treatment can gain treatment effects similar to those of the sertraline, with less adverse reactions.
分析A型肉毒毒素（BtA）治疗帕金森病伴抑郁患者的效果。
采用随机数字表法将89例帕金森病伴抑郁患者分为对照组和观察组，对照组44例采用舍曲林治疗，观察组45例采用BtA治疗。比较两组患者的情绪、认知功能及不良反应。
两组治疗后的汉密尔顿抑郁自评量表（HAMD）评分均低于治疗前，简易精神状态检查表（MMSE）评分均高于治疗前（P<0.05）。观察组不良事件发生率为11.11%，低于对照组的29.55%（P<0.05）。治疗2、3个月及治疗结束后2个月的匹兹堡睡眠质量指数（PSQI）评分及帕金森病39项问卷（PDQ-39）评分均低于治疗前（P<0.05）。
帕金森病伴抑郁患者接受BtA治疗可获得与舍曲林相似的治疗效果，且不良反应较少。
